reboxetine has been researched along with oxybutynin in 3 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | reboxetine (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azarbarzin, A; Lombardi, C; Marconi, M; Meriggi, P; Parati, G; Perger, E; Rosa, D; Sands, SA; Taranto Montemurro, L; Vicini, S; Wellman, A; Zanotti, L | 1 |
| Azarbarzin, A; Baratto, C; Caravita, S; Castiglioni, P; Faini, A; Lombardi, C; Meriggi, P; Parati, G; Perger, E; Pini, L; Rosa, D; Soranna, D; Vicini, S; Zambon, A | 1 |
| Bayon, V; Berger, M; Bradley, B; Dussez, R; Haba-Rubio, J; Heiniger, G; Heinzer, R; Lecciso, G; Marchi, NA; Siclari, F; Solelhac, G; Van Den Broecke, S | 1 |
3 trial(s) available for reboxetine and oxybutynin
| Article | Year |
|---|---|
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Topics: Adrenergic Uptake Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Polysomnography; Reboxetine; Severity of Illness Index; Sleep Apnea, Obstructive; Treatment Outcome | 2022 |
Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation.
Topics: Autonomic Nervous System; Blood Pressure Monitoring, Ambulatory; Heart Rate; Humans; Middle Aged; Reboxetine; Sleep Apnea, Obstructive | 2023 |
Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial.
Topics: Cross-Over Studies; Double-Blind Method; Humans; Male; Oxygen; Reboxetine; Sleep Apnea, Obstructive | 2023 |